Continued oncology pipeline advancement with a strategic focus on two priority pan-tumor programs: next-generation immunomodulator BNT327, a bispecific antibody targeting PD-L1 and VEGF-A1, and mRNA c ...

BioNTech invites investors and the general public to join a conference call and webcast with investment analysts today, May 5, 2025, at 8:00 a.m. EDT (2:00 p.m. CEST) to report its financial results ...

The Trump administration’s unprecedented $500 million grant for a broadly protective flu shot has confounded vaccine and ...

Immunization is one of the most cost-effective public health interventions in history. Backed by extensive global and local data, the impact of vaccines on healthcare systems and populations is clear ...